Scarica l'app Stockscreener
686.36
6.21%
-45.41
Pre-mercato:
680.01
-6.35
-0.93%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Regeneron Pharmaceuticals Inc (REGN) Q1 2026 Earnings Call Highl - GuruFocus
Could Cash Machine Regeneron Pharmaceuticals Stock Be Your Next Buy? - Trefis
REGN SWOT Analysis: Financial Strength and Growth Opportunities Revealed in 10-Q Filing - GuruFocus
Regeneron Pharmaceuticals (REGN) Margins Hold Near 31% Challenging Bearish Profitability Narratives - simplywall.st
Truist cuts Regeneron stock price target on FDA approval delay By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Plans $0.94 Quarterly Dividend - MarketBeat
Regeneron Stock Tumbles on Earnings. Upcoming Data Matter More for the Stock. - Barron's
Regeneron Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Regeneron Pharmaceuticals (NASDAQ:REGN) Announces Quarterly Earnings Results - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 7.8%Here's What Happened - MarketBeat
Regeneron Pharmaceuticals Delivers 19% Revenue Growth in Q1 2026 - AlphaStreet
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement - TradingKey
Raymond James cuts Regeneron stock price target on Eylea HD miss - Investing.com Canada
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe - Benzinga
Regeneron Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Regeneron shares fall 5% on Eylea sales decline, regulatory delays By Investing.com - Investing.com Canada
Regeneron Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Oil Surges 6%, S&P 500 Wobbles Before Fed And Tech Earnings: Stock Market Today - Benzinga
Regeneron beats quarterly estimates on Dupixent demand; shares fall on Eylea weakness - Reuters
Intel, NXP Semiconductors, Seagate, Bloom Energy, Avis, Regeneron, Robinhood, and More Stock Movers - Barron's
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength - Yahoo Finance
Regeneron’s C5 Milestones And Autoimmune Bets Shape Future Valuation - Yahoo Finance
Regeneron Pharmaceuticals, Inc. announces an Equity Buyback for $3,000 million worth of its shares. - marketscreener.com
Tranche Update on Regeneron Pharmaceuticals, Inc.'s Equity Buyback Plan announced on February 4, 2025. - marketscreener.com
Regeneron basks in first gene therapy approval as Dupixent, Eylea carry robust Q1 earnings - BioSpace
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength (NASDAQ:REGN) - Seeking Alpha
Earnings call transcript: Regeneron Q1 2026 beats estimates, stock dips - Investing.com
Regeneron drops despite Q1 beat, $3B share buyback program - MSN
Regeneron shares slide despite Q1 beat - Yahoo! Finance Canada
Regeneron beats quarterly estimates on strong Dupixent demand - WHTC
Regeneron Pharmaceuticals (REGN) Reports Strong Q1 2026 Earnings and Announces $3B Buyback - GuruFocus
Is Regeneron (REGN) Still 23.3% Undervalued After Q1 2026? Non-G - GuruFocus
Regeneron Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:REGN) 2026-04-29 - Seeking Alpha
Regeneron (REGN) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo! Finance Canada
Regeneron tops Q1 estimates on Dupixent momentum - MSN
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock - TechStock²
Regeneron stock drops despite Q1 beat (REGN:NASDAQ) - Seeking Alpha
Regeneron Tops Q1 Estimates on Dupixent Momentum - Yahoo Finance
Regeneron (REGN) Reports Strong Q1 Revenue and New Drug Pricing Initiative - GuruFocus
Regeneron (REGN) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance Australia
Regeneron beats quarterly results estimates on strong Dupixent demand - Yahoo Finance
Regeneron Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
Regeneron beats first quarter estimates on Dupixent strength By Investing.com - Investing.com Nigeria
REGENERON PHARMACEUTICALS ($REGN) Releases Q1 2026 Earnings - Quiver Quantitative
Mitsubishi UFJ Trust & Banking Corp Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Reports First Quarter 2026 Financial and Operating Results - The Manila Times
Regeneron (NASDAQ:REGN) Reports Strong Q1 CY2026 - Yahoo Finance
Regeneron: Q1 Earnings Snapshot - KTVB
Certuity LLC Reduces Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron strikes deal with Trump administration to cut drug prices - MSN
Is It Too Late To Consider Regeneron (REGN) After Its 29% One-Year Rally? - Yahoo Finance
Hemophilia B Pipeline Set for Transformational Breakthroughs - openPR.com
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
How Will Regeneron Pharmaceuticals Stock React To Its Upcoming Earnings? - Trefis
Kiniksa posts Q1 beat thanks to Regeneron drug (KNSA:NASDAQ) - Seeking Alpha
Regeneron CEO defends pharma, warns China will ‘pass us right by’ after announcing free gene therapy for hearing loss - MSN
Regeneron (REGN) Q1 Earnings Report Preview: What To Look For - Yahoo Finance
Did Gene Therapy Milestones and Dupixent Expansion Just Shift Regeneron Pharmaceuticals' (REGN) Investment Narrative? - simplywall.st
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings? - Yahoo Finance
Regeneron: Catching Another Wind (NASDAQ:REGN) - Seeking Alpha
Pictet Asset Management Holding SA Purchases 44,500 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi and Regeneron’s Dupixent becomes first biologic for kids under 12 with CSU - MSN
Vanguard Group Inc. Raises Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis: Unveiling a 16.82% Upside Potential - DirectorsTalk Interviews
TD Cowen Lifts PT on Regeneron Pharmaceuticals (REGN) Ahead of Fiscal Q1 Results - Insider Monkey
0.13%
0.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):